Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bio-Rad Laboratories, Inc. BIO
$369.96
+$5.71 (1.54%)
На 18:00, 12 мая 2023
+52.72%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
11204414862.00000000
-
week52high
572.70
-
week52low
344.63
-
Revenue
2802249000
-
P/E TTM
-3
-
Beta
0.90830400
-
EPS
-121.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Citigroup | Buy | Buy | 08 июл 2022 г. |
| Wells Fargo | Overweight | Overweight | 30 июл 2021 г. |
| Citigroup | Buy | Buy | 12 февр 2021 г. |
| Jefferies | Buy | Buy | 05 февр 2021 г. |
| Credit Suisse | Outperform | Outperform | 28 окт 2022 г. |
| RBC Capital | Outperform | 07 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| WRIGHT DARA | D | 1005 | 502 | 16 дек 2022 г. |
| WRIGHT DARA | D | 1762 | 226 | 16 дек 2022 г. |
| WRIGHT DARA | A | 1988 | 502 | 16 дек 2022 г. |
| RAMALINGAM AJIT | D | 0 | 0 | 10 ноя 2022 г. |
| RAMALINGAM AJIT | D | 0 | 112 | 10 ноя 2022 г. |
| RAMALINGAM AJIT | D | 112 | 267 | 10 ноя 2022 г. |
| SCHWARTZ STEVEN D | A | 12900 | 42 | 07 ноя 2022 г. |
| SCHWARTZ STEVEN D | A | 25128 | 42 | 07 ноя 2022 г. |
| SCHWARTZ NORMAN D | A | 12900 | 42 | 07 ноя 2022 г. |
| SCHWARTZ NORMAN D | A | 331689 | 42 | 07 ноя 2022 г. |
Новостная лента
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
Zacks Investment Research
05 мая 2023 г. в 09:09
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 22:48
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Ed Chung - Vice President, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Dan Leonard - Credit Suisse Jack Meehan - Nephron Research Operator Good afternoon. Thank you for attending the Bio-Rad First Quarter 2023 Earnings Conference Call.
Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
Zacks Investment Research
01 мая 2023 г. в 11:25
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
Zacks Investment Research
26 апр 2023 г. в 09:54
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
Zacks Investment Research
24 апр 2023 г. в 08:24
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.